Toggle Main Menu Toggle Search

Open Access padlockePrints

Sensitivity of novel silicate and borate-based glass structures on in vitro bioactivity and degradation behaviour

Lookup NU author(s): Elena Mancuso, Dr Oana Bretcanu, Professor Kenneth Dalgarno

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2017. Three novel glass compositions, identified as NCL2 (SiO2-based), NCL4 (B2O3-based) and NCL7 (SiO2-based), along with apatite-wollastonite (AW) were processed to form sintered dense pellets, and subsequently evaluated for their in vitro bioactive potential, resulting physico-chemical properties and degradation rate. Microstructural analysis showed the carbonated hydroxyapatite (HCA) precipitate morphology following SBF testing to be composition-dependent. AW and the NCL7 formulation exhibited greater HCA precursor formation than the NCL2 and NCL4-derived pellets. Moreover, the NCL4 borate-based samples showed the highest biodegradation rate; with silicate-derived structures displaying the lowest weight loss after SBF immersion. The results of this study suggested that glass composition has significant influence on apatite-forming ability and also degradation rate, indicating the possibility to customise the properties of this class of materials towards the bone repair and regeneration process.


Publication metadata

Author(s): Mancuso E, Bretcanu O, Marshall M, Dalgarno KW

Publication type: Article

Publication status: Published

Journal: Ceramics International

Year: 2017

Volume: 43

Issue: 15

Pages: 12651-12657

Print publication date: 15/10/2017

Online publication date: 24/06/2017

Acceptance date: 23/06/2017

Date deposited: 23/06/2017

ISSN (print): 0272-8842

ISSN (electronic): 1873-3956

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.ceramint.2017.06.146

DOI: 10.1016/j.ceramint.2017.06.146


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
19429VERSUS Arthritis (formerly Arthritis Research UK)
280575
EP/K029592

Share